Repatha Pediatric (Under Age 12): Caregiver Administration Guidance

Why Evolocumab Is Prescribed for Children Under 12 and Those Close to That Age

Evolocumab targets and inhibits PCSK9, a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, the drug increases LDL receptor recycling and lowers circulating LDL cholesterol substantially. This mechanism matters especially in HoFH, where both copies of the LDLR gene are mutated, leaving children with LDL-C levels that can exceed 400 mg/dL from birth. Untreated, those levels drive atherosclerosis decades before adulthood.

The HoFH Burden in Pediatric Patients

HoFH affects roughly 1 in 300,000 to 1 in 1,000,000 people worldwide, but its cardiovascular consequences appear in childhood. The European Atherosclerosis Society consensus states that aortic stenosis and coronary artery disease can manifest in the first decade of life in untreated patients. Statins and ezetimibe rarely bring LDL-C to goal in true HoFH. Lipoprotein apheresis, the previous standard, requires biweekly clinic visits and vascular access in small children, a significant burden.

FDA Approval Pathway for Pediatric Use

The FDA granted approval for evolocumab in pediatric HoFH patients aged 10 and older in August 2021, based on the HAUSER-RCT and HAUSER-OLE trials. The approval label is available in full on the FDA's accessdata portal. The label explicitly restricts the pediatric indication to HoFH; heterozygous familial hypercholesterolemia (HeFH) in children under 12 does not carry an FDA-approved indication for evolocumab as of the 2025 review date.

The Clinical Evidence Base Caregivers Should Understand

Before learning injection technique, caregivers benefit from knowing what the clinical data actually show. That context shapes realistic expectations for LDL-C response.

HAUSER-RCT: The Key Pediatric Trial

HAUSER-RCT enrolled 104 patients aged 10 to 17 with HoFH. Published in the New England Journal of Medicine in 2020, the trial randomized patients 2:1 to evolocumab 420 mg monthly versus placebo for 24 weeks on top of optimized background therapy. Mean LDL-C reduction was 19.3% with evolocumab versus a 1.5% increase with placebo (P<0.001). The authors wrote: "Evolocumab significantly reduced LDL cholesterol levels in children and adolescents with HoFH with an adverse-event profile similar to that seen in adults."

That 19.3% reduction is clinically meaningful. In a child starting at 400 mg/dL, it translates to roughly 77 mg/dL removed from circulation each month, on top of whatever statins and ezetimibe are already doing. Baseline LDL-C in HoFH pediatric cohorts averages near 500 mg/dL even on background lipid therapy, according to registry data published in JACC.

HAUSER-OLE: Long-Term Safety Data

The open-label extension (HAUSER-OLE) followed participants for an additional 96 weeks. Results published in the Lancet showed that the LDL-C reduction was sustained, with no new safety signals emerging over approximately 2 years of pediatric exposure. Adverse event rates were consistent with the adult experience: injection-site reactions occurred in about 5% of participants, and serious adverse events were rare and not attributed to the drug.

FDA-Approved Dosing for Pediatric HoFH

Dose is straightforward. Children aged 10 and older with HoFH receive 420 mg subcutaneously once every 4 weeks. The prescribing information specifies three delivery options for the 420 mg dose.

Three Device Options for the 420 mg Dose

1. Three consecutive 140 mg SureClick autoinjector injections, administered one after another in different sites on the same day.
2. Three consecutive 140 mg prefilled syringe injections, same protocol.
3. One 420 mg/3.5 mL Pushtronex on-body infusor, which delivers the full dose over approximately 9 minutes via a single application site.

For most caregiver-administered home doses in children, the SureClick autoinjector is the most practical device. The Pushtronex device requires attaching to skin and waiting; some younger children find the longer application difficult. Discuss device preference with the prescribing physician before the first home dose.

Dose Adjustments and Missed Doses

No weight-based dose adjustment exists in the current label for patients aged 10 and older. The FDA label does not specify a reduced dose for lower body-weight pediatric patients within the approved age range. If a dose is missed, give it as soon as possible if the next scheduled dose is more than 2 weeks away. If the next scheduled dose is within 2 weeks, skip the missed dose and resume the regular monthly schedule.

Step-by-Step Caregiver Injection Technique

Precise technique reduces injection-site reactions and ensures full dose delivery. Review this section before the first home injection and refresh periodically.

Preparation: Before You Open the Package

Gather supplies: the autoinjector (or prefilled syringe), alcohol swabs, a sharps disposal container, and a clean flat surface. Wash hands with soap and water for at least 20 seconds. Proper hand hygiene before subcutaneous injection is a CDC-recommended standard for home drug administration.

Remove the device from the refrigerator 30 minutes before injection. Cold product stings more and may not dispense smoothly. Do not warm the device with hot water or a microwave.

Check the expiration date on the label. Inspect the solution through the viewing window: it should be clear to slightly opalescent and colorless to pale yellow. The FDA label states the product should not be used if it is discolored or contains visible particles.

Selecting and Preparing the Injection Site

Approved sites are the abdomen (at least 2 inches from the navel), the front of the thigh, or the outer upper arm. Rotate sites with each injection. Never inject into skin that is bruised, red, tender, tattooed, or scarred.

Clean the chosen site with an alcohol swab using a circular motion. Allow it to air-dry for 10 seconds. Do not fan or blow on the skin.

The SureClick Autoinjector: Injection Steps

1. Remove the orange cap by pulling it straight off. Do not twist.
2. Place the flat end of the device firmly against the cleaned skin at a 90-degree angle.
3. Press down firmly until a click is heard. This starts the injection.
4. Hold the device in place until a second click is heard (approximately 15 seconds). The second click signals dose completion.
5. Lift the device straight away from the skin. The orange needle guard will automatically cover the needle.
6. Check the viewing window: it should appear yellow, confirming full dose delivery.
7. Dispose of the used device immediately in an FDA-cleared sharps container. Proper sharps disposal instructions are provided by the FDA to prevent needlestick injury.

The Prefilled Syringe: Injection Steps

1. Hold the syringe by the barrel, not the plunger or the needle shield.
2. Pull the needle shield straight off. Do not recap after removal.
3. Pinch a fold of skin at the prepared site.
4. Insert the needle at a 45 to 90-degree angle, depending on the child's body composition.
5. Push the plunger slowly and steadily until the barrel is empty.
6. Release the skin fold, then withdraw the needle at the same angle used for insertion.
7. Apply gentle pressure with a dry gauze pad for 10 seconds. Do not rub.
8. Dispose of the syringe in a sharps container.

After the Injection

Record the date, dose, device used, and injection site in a medication log. The American Heart Association recommends medication logs for pediatric cardiovascular drug regimens to support adherence monitoring at clinical visits. Monitor the child for at least 30 minutes after the first home injection for any signs of hypersensitivity.

Storage and Handling

Evolocumab must be stored in the original carton to protect from light. The prescribing information states: refrigerate at 2°C to 8°C (36°F to 46°F). Do not freeze. If refrigeration is temporarily unavailable, the product may be stored at room temperature up to 25°C (77°F) for a maximum of 30 days. Once the product has been at room temperature, it must not be returned to the refrigerator and should be used within that 30-day window or discarded.

Travel Considerations

Use an insulated cooler bag with a cold pack (not direct ice contact) during travel. Do not check insulin or biologic medications in airplane cargo holds, where temperatures can drop below freezing. TSA permits autoinjectors in carry-on luggage; carry the original pharmacy label and a copy of the prescription. Biologic storage during travel is addressed in general CDC guidelines for travelers on injectable medications.

Monitoring: What to Watch for at Home and in the Clinic

Signs of Injection-Site Reactions

Local reactions are the most common side effect in pediatric trials. Redness, swelling, bruising, or pain at the injection site typically resolves within 2 to 3 days. Apply a cool compress for comfort. If a reaction persists beyond 5 days, spreads, or is accompanied by fever, contact the prescribing physician.

Signs of Serious Hypersensitivity

Rare cases of angioedema, rash, and urticaria have been reported with evolocumab. The FDA label lists hypersensitivity reactions, including angioedema, as a reason for permanent discontinuation. Signs include hives, swelling of the face or throat, difficulty breathing, or rapid heart rate. Call 911 immediately if these symptoms appear.

Laboratory Monitoring Schedule

Obtain a fasting lipid panel 4 to 12 weeks after starting therapy to confirm response. AACE clinical practice guidelines recommend periodic lipid monitoring for patients on PCSK9 inhibitor therapy to assess efficacy and guide combination treatment decisions. After confirmed response, most pediatric HoFH programs check lipids every 3 months for the first year, then at least annually. Liver function tests and creatine kinase are not required routinely by the label but may be checked at the clinician's discretion.

Cognitive and Neurodevelopmental Monitoring

Adult trials raised early concerns about neurocognitive effects with PCSK9 inhibitors. The large FOURIER trial (N=27,564) and a dedicated neurocognitive substudy found no statistically significant difference in cognitive function between evolocumab and placebo. FOURIER trial results are published in the New England Journal of Medicine. Long-term pediatric neurodevelopmental data beyond 2 years remain limited, so caregivers should report any unusual changes in school performance or behavior at routine clinical visits.

Combination Therapy Context

Evolocumab in pediatric HoFH is nearly always added to background therapy. HAUSER-RCT required patients to be on stable maximally tolerated statin therapy, with or without ezetimibe, for at least 4 weeks before enrollment. The drug's effect was additive: the 19.3% LDL-C reduction occurred on top of existing reductions from statins and ezetimibe.

When Lipoprotein Apheresis Is Still Needed

Some children with the most severe LDLR mutations achieve less than 10% LDL-C reduction with evolocumab. This subgroup typically carries two null LDLR mutations and has virtually no functional LDL receptor activity. The European Atherosclerosis Society consensus paper notes that patients with null/null LDLR genotypes respond less well to PCSK9 inhibitors because the mechanism requires at least some residual receptor function. For these children, lipoprotein apheresis or lomitapide may remain necessary alongside evolocumab.

Drug Interactions

No significant pharmacokinetic drug interactions have been identified for evolocumab. The prescribing information states that evolocumab is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes. Caregivers should still inform all providers and pharmacists of every medication the child takes, including supplements, because lipid-modifying regimens are often complex.

Adherence Strategies for Pediatric Patients

Monthly injections are far less frequent than daily oral medications, which helps adherence. Still, children can develop anticipatory anxiety around injections. A few practical approaches help.

Involve the child in age-appropriate decisions, such as choosing the injection site. Use distraction techniques: a video, music, or a counting game during the 15-second hold. Pediatric pain management guidelines from the AAP support non-pharmacologic distraction as an effective technique for procedural pain in children. Topical anesthetic cream (EMLA or LMX4) applied 45 to 60 minutes before injection reduces the sting of the needle entry for particularly needle-anxious children.

Set a recurring calendar reminder for the same day each month. Store the medication log next to the sharps container so documentation happens immediately after each dose.

When to Contact the Medical Team

Call the prescribing provider if:

• The child has a fever above 38.5°C on the day of the scheduled injection.
• The viewing window on the autoinjector does not turn yellow after injection.
• Any dose is accidentally double-administered.
• The child develops persistent muscle pain or weakness (to rule out statin-related myopathy in combination regimens, not attributed to evolocumab in trials but worth flagging).
• LDL-C is not meaningfully reduced on the first follow-up lipid panel. Lack of LDL-C response in HoFH may signal a null/null LDLR genotype requiring genotyping or apheresis re-evaluation, as noted in JACC registry analyses.

Call 911 immediately for signs of anaphylaxis or severe hypersensitivity as listed above.

Insurance, Prior Authorization, and Access Programs

PCSK9 inhibitors remain among the more expensive lipid therapies on the market. Most insurers require prior authorization, typically demanding documentation of an HoFH diagnosis (genetic confirmation or clinical criteria), a trial of maximally tolerated statin therapy, and an LDL-C above a threshold despite that therapy. FDA approval for a pediatric indication does not automatically trigger payer coverage; the National Lipid Association has published guidance on navigating PCSK9 inhibitor prior authorization for high-risk patients.

Amgen offers the Repatha Copay Card and the Amgen Safety Net Foundation for eligible patients. Ask the prescribing clinic's financial counselor for enrollment forms at the first visit.